Open Orphan plc changes its name to hVIVO plc, learn more
here
.
About Us
About hVIVO
Leadership Team
Our Companies
Key Stats
History
Services
New
Challenge Trials
RSV
Influenza
COVID-19
HRV
Malaria
Asthma & COPD
hMPV
Phase II-III Trials
Vaccine Phase II-III Trials
Laboratory Services
Assay Development
Field Trial Bio-logistics
Cell Based Assays
Molecular Services
Compound Efficacy & VRM
Biomarker Analysis
Articles & Research
News & Media
Regulatory News
Media Coverage
Media Press Kit
Video Library
Events
Investors
New
Investors
Regulatory News & Email Alerts
Results Centre
Share Price Information
Events & Presentations
Environmental, Social & Governance
AIM Rule 26
Advisors
Documents
Corporate Governance
Volunteers
Careers
Contact Us
Contact Us
22 Mar 2023
Go Back
Utilising Human Challenge Trials as a tool in expedited review programs for infectious diseases
Share this:
Featured on pages 18-19
Other recent posts
Case Study
SARS-CoV-2 Human Challenge Study
At the start of the Covid pandemic, as the world leader in human challenge studies, hVIVO acted as prime contractor in a UK Government funded consortium tasked with setting up...
Read more
Blog
Human Challenge Trials for Tropical Diseases: Not as exotic as one might think
Introduction Despite scientific progress made in the last decades, nearly 1 billion of individuals are affected by tropical diseases yearly, according to the World Health Organization. The development of new...
Read more
If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.
Contact hVIVO
facebook
envelope
linkedin
angle-down
xing
paper-plane
pinterest-p
whatsapp
commenting
meetup
chevron-down